An eight-week randomized, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5mg versus amlodipine 10mg monotherapy in patients with hypertension who fail to respond adequately to treatment with amlodipine 5mg monotherapy.

Trial Profile

An eight-week randomized, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5mg versus amlodipine 10mg monotherapy in patients with hypertension who fail to respond adequately to treatment with amlodipine 5mg monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Amlodipine/telmisartan (Primary) ; Amlodipine
  • Indications Essential hypertension; Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TEAMSTA-5
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2011 Results published in the Journal of Clinical Hypertension (Greenwich).
    • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
    • 27 Jul 2010 European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA based on the results of this trial and TEAMSTA-10 and TEAMSTA Severe HTN, according to a Boehringer-Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top